The effect of recombinant human soluble thrombomodulin on renal function and mortality in septic disseminated intravascular coagulation patients with acute kidney injury: a retrospective study

Table 2 Odds ratios regarding the primary and secondary outcomes in the rhTM and non-rhTM groups

	rhTM group (n = 52)	Non-rhTM group (n = 45)	Regression coefficient	OR (95% CI)	P value
Primary outcome
Dependence on RRT at ICU discharge—no. (%)	21 (40.4)	28 (62.2)	− 0.86	0.43 (0.19–0.97)	0.043
Secondary outcomes
Serum creatinine level (mg/dL)
at ICU admission	2.00 (1.19–2.87)	2.30 (1.50–3.14)	− 0.39	0.67 (0.30–1.52)	0.34
at ICU discharge	1.22 (0.77–1.75)	2.23 (1.09–2.94)	− 1.18	0.31 (0.13–0.72)	0.007
at hospital discharge	1.00 (0.74–1.62)	1.98 (1.04–2.94)	− 1.37	0.25 (0.11–0.60)	0.002
RRT-free days for 28 days	15 (0–21)	0 (0–21)	1.06	2.89 (1.24–6.74)	0.014
ICU-free days for 28 days	13 (0–20)	0 (0–17)	0.90	2.47 (1.07–5.67)	0.033
Ventilator-free days for 28 days	20 (0–23)	0 (0–24)	1.20	3.31 (1.41–7.75)	0.006
Mortality
ICU—no. (%)	18 (34.6)	22 (48.9)	− 0.59	0.56 (0.24–1.28)	0.17
28 days—no. (%)	15 (28.8)	23 (51.0)	− 0.92	0.40 (0.17–0.93)	0.033

Data are presented as medians (IQR). The ICU-free and mechanical ventilation-free days were calculated according to the number of days in which the patient was alive and did not receive the specified therapy during the first 28 days after enrollment; patients who died were assigned as having 0 free days. The number of RRT-free days was calculated according to the number of days in which the patient did not receive RRT during the first 28 days after enrollment
RRT renal replacement therapy, ICU intensive care unit, IQR interquartile range, OR odds ratio, 95% CI 95% confidence interval, rhTM recombinant human soluble thrombomodulin

ISSN: 2052-0492